X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4473) 4473
Book Chapter (9) 9
Magazine Article (9) 9
Dissertation (3) 3
Newsletter (3) 3
Publication (2) 2
Conference Proceeding (1) 1
Government Document (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3837) 3837
male (2432) 2432
female (2268) 2268
benzimidazoles - therapeutic use (2239) 2239
benzimidazoles - adverse effects (2106) 2106
middle aged (1655) 1655
aged (1394) 1394
benzimidazoles - administration & dosage (1342) 1342
adult (1271) 1271
treatment outcome (995) 995
dabigatran (897) 897
pharmacology & pharmacy (843) 843
benzimidazoles - pharmacology (832) 832
animals (818) 818
beta-alanine - analogs & derivatives (698) 698
hypertension - drug therapy (613) 613
double-blind method (594) 594
drug therapy, combination (523) 523
anticoagulants - adverse effects (468) 468
beta-alanine - adverse effects (462) 462
administration, oral (450) 450
aged, 80 and over (448) 448
hypertension (448) 448
drug therapy (438) 438
dose-response relationship, drug (426) 426
blood pressure - drug effects (421) 421
benzimidazoles - pharmacokinetics (417) 417
peripheral vascular disease (397) 397
warfarin (374) 374
2-pyridinylmethylsulfinylbenzimidazoles (368) 368
antihypertensive agents - therapeutic use (362) 362
angiotensin ii type 1 receptor blockers - therapeutic use (359) 359
gastroenterology & hepatology (359) 359
tetrazoles - therapeutic use (350) 350
risk factors (348) 348
anticoagulants - therapeutic use (344) 344
cardiac & cardiovascular systems (343) 343
adolescent (341) 341
atrial fibrillation - drug therapy (337) 337
medicine, general & internal (334) 334
prevention (330) 330
rivaroxaban (324) 324
benzoates - therapeutic use (319) 319
abridged index medicus (315) 315
efficacy (315) 315
rats (311) 311
omeprazole - analogs & derivatives (307) 307
beta-alanine - therapeutic use (306) 306
therapy (305) 305
oncology (304) 304
hemorrhage - chemically induced (299) 299
telmisartan (294) 294
analysis (292) 292
prospective studies (291) 291
double-blind (285) 285
pharmacokinetics (283) 283
anticoagulants (281) 281
medicine & public health (280) 280
care and treatment (278) 278
stroke - prevention & control (276) 276
time factors (276) 276
atrial fibrillation (268) 268
anticoagulants - administration & dosage (266) 266
research (257) 257
antithrombins - adverse effects (256) 256
safety (255) 255
health aspects (250) 250
beta-alanine - administration & dosage (249) 249
antihypertensive agents - adverse effects (247) 247
clinical trials as topic (245) 245
drug interactions (240) 240
randomized controlled trials as topic (240) 240
management (234) 234
omeprazole (233) 233
clinical trials (230) 230
candesartan (229) 229
drug administration schedule (225) 225
atrial fibrillation - complications (224) 224
stroke (222) 222
dabigatran etexilate (220) 220
internal medicine (213) 213
mice (211) 211
dosage and administration (210) 210
angiotensin-converting enzyme inhibitors - therapeutic use (207) 207
warfarin - adverse effects (206) 206
hypertension - physiopathology (203) 203
mortality (203) 203
pyridines - adverse effects (202) 202
young adult (202) 202
proton pump inhibitors (201) 201
risk (196) 196
hepatitis c, chronic - drug therapy (195) 195
angiotensin ii type 1 receptor blockers - adverse effects (194) 194
benzoates - adverse effects (193) 193
antiviral agents - therapeutic use (191) 191
follow-up studies (191) 191
morpholines - therapeutic use (191) 191
morpholines - adverse effects (190) 190
pyridines - therapeutic use (189) 189
thiophenes - therapeutic use (188) 188
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4208) 4208
German (110) 110
French (58) 58
Russian (57) 57
Japanese (48) 48
Spanish (35) 35
Chinese (12) 12
Portuguese (8) 8
Danish (7) 7
Hungarian (7) 7
Italian (7) 7
Czech (6) 6
Dutch (4) 4
Polish (4) 4
Swedish (4) 4
Finnish (2) 2
Norwegian (2) 2
Korean (1) 1
Lithuanian (1) 1
Serbian (1) 1
Turkish (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The oncologist (Dayton, Ohio), ISSN 1549-490X, 2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
.... Risk ratios (RR) for VTE and bleed end-points were estimated using fixed and random effects meta-analysis... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
European journal of gastroenterology & hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 2014, Volume 129, Issue 7, pp. 764 - 772
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those... 
Antagonists & inhibitors | Recurrence | Thrombin | Warfarin | Hemorrhage | Venous thromboembolism | CARDIAC & CARDIOVASCULAR SYSTEMS | FONDAPARINUX | THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | RIVAROXABAN | INITIAL TREATMENT | PERIPHERAL VASCULAR DISEASE | ORAL ANTICOAGULANT-THERAPY | APIXABAN | UNFRACTIONATED HEPARIN | Anticoagulants - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Heparin - administration & dosage | Heparin, Low-Molecular-Weight - adverse effects | Warfarin - adverse effects | Male | Antithrombins - administration & dosage | Dabigatran | Heparin - adverse effects | Warfarin - administration & dosage | Venous Thromboembolism - drug therapy | Young Adult | Benzimidazoles - administration & dosage | Adult | Female | Benzimidazoles - adverse effects | Venous Thromboembolism - epidemiology | beta-Alanine - analogs & derivatives | Acute Disease | beta-Alanine - adverse effects | Double-Blind Method | Hemorrhage - epidemiology | Risk Factors | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Antithrombins - adverse effects | Adolescent | Aged | Hemorrhage - chemically induced | Heparin, Low-Molecular-Weight - administration & dosage | Usage | Care and treatment | Dabigatran etexilate | Thromboembolism | Anticoagulants | Benzimidazoles | Heparin, Low-Molecular-Weight | Life Sciences | Venous Thromboembolism | Antithrombins | Heparin | beta-Alanine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 03/2012, Volume 107, Issue 3, pp. 584 - 589
Journal Article
The Lancet infectious diseases, ISSN 1473-3099, 2015, Volume 15, Issue 6, pp. 645 - 653
Summary Background Compared with other countries, patients with chronic hepatitis C infection in Japan tend to be older, have more advanced liver disease, and... 
Infectious Disease | INFECTIOUS DISEASES | SIMEPREVIR | INFECTION | CHRONIC HCV | Uridine Monophosphate - administration & dosage | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Drug-Related Side Effects and Adverse Reactions - pathology | Young Adult | Benzimidazoles - administration & dosage | Time Factors | Ribavirin - administration & dosage | Aged, 80 and over | Adult | Female | Fluorenes - administration & dosage | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Hepacivirus - isolation & purification | Administration, Oral | Japan | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Asian Continental Ancestry Group | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Aged | Hepacivirus - classification | Sofosbuvir | Care and treatment | Liver | Dosage and administration | Product development | Drug therapy, Combination | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Hepatitis | Genotype & phenotype | Liver cancer | Heart attacks | Liver diseases | Human immunodeficiency virus--HIV | Hepatology | Response rates | Interferon | Infections | Drug dosages | Patients
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 09/2012, Volume 108, Issue 3, pp. 476 - 484
New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation. Two... 
anticoagulants | Stroke | Atrial fibrillation | Review Article | Anticoagulants | COST-EFFECTIVENESS | EVENTS | STROKE PREVENTION | RISK | PHARMACODYNAMICS | stroke | PHARMACOKINETICS | WARFARIN | ORAL ANTICOAGULANTS | ANTITHROMBOTIC THERAPY | ETEXILATE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Thiophenes - therapeutic use | Pyrazoles - therapeutic use | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Warfarin - adverse effects | Male | Secondary Prevention | Dabigatran | Thrombophilia - etiology | Warfarin - therapeutic use | Rivaroxaban | Vitamin K - antagonists & inhibitors | Ischemic Attack, Transient - prevention & control | Clinical Trials, Phase III as Topic - statistics & numerical data | Heart Valve Diseases - complications | Female | Stroke - epidemiology | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Embolism - epidemiology | Morpholines - adverse effects | Morpholines - therapeutic use | Thrombophilia - drug therapy | Benzimidazoles - therapeutic use | Pyrazoles - adverse effects | Severity of Illness Index | Multicenter Studies as Topic - statistics & numerical data | Randomized Controlled Trials as Topic - statistics & numerical data | Stroke - prevention & control | beta-Alanine - adverse effects | Embolism - prevention & control | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Antithrombins - therapeutic use | Atrial Fibrillation - complications | beta-Alanine - therapeutic use | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ischemic Attack, Transient - epidemiology | Antithrombins - adverse effects | Aged | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects
Journal Article
Contemporary Clinical Trials, ISSN 1551-7144, 2017, Volume 57, pp. 58 - 68
... (T4), 12 months post-treatment (T5). Outcomes (1) Changes in side effects, functioning, pre-existing conditions, and out-of-pocket costs during therapy (T1 vs T2/T3); (2... 
Hematology, Oncology and Palliative Medicine | Cardiovascular | Hepatitis | Direct acting antiviral (DAA) | Patient-reported outcomes | Patient-centered outcomes research (PCOR) | Liver | UNITED-STATES | MEDICINE, RESEARCH & EXPERIMENTAL | REPORTED OUTCOMES | VIRUS-INFECTION | HCV GENOTYPE 1 | SYMPTOM PREVALENCE | NATIONAL-HEALTH | INFORMATION-SYSTEM PROMIS | PSYCHOMETRIC EVALUATION | ROBUST ESTIMATION | PHARMACOLOGY & PHARMACY | QUALITY-OF-LIFE | Quinoxalines - adverse effects | Prospective Studies | Humans | Patient Participation | Fluorenes - therapeutic use | Male | Ritonavir - adverse effects | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Patient-Centered Care - methods | Ritonavir - therapeutic use | Adult | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Quinoxalines - therapeutic use | Uridine Monophosphate - therapeutic use | Sofosbuvir - therapeutic use | Benzofurans - therapeutic use | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Uracil - therapeutic use | Heterocyclic Compounds, 4 or More Rings - adverse effects | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Benzofurans - adverse effects | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | Sulfonamides - adverse effects | Carbamates - adverse effects | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Medicine, Experimental | Medical research | Antiviral agents | Hepatitis C | Drug therapy | Hepatitis C virus | Analysis | patient-reported outcomes | patient-centered outcomes research (PCOR) | hepatitis | direct acting antiviral (DAA)
Journal Article